At ASCO 2026, European pharma firms had a quiet showing, but AstraZeneca and Roche faced key challenges. AstraZeneca's lung cancer drug Datroway competes with Merck's sac-TMT, which showed strong efficacy but high toxicity, making AstraZeneca's biomarker strategy crucial. AstraZeneca's anselamimab showed promise in a rare amyloidosis subgroup despite a failed trial. Roche's breast cancer drug giredestrant was praised for tolerability but awaits mature data, while its lung cancer drug divarasib showed efficacy with serious toxicity concerns. These developments impact future approvals and market potential.
Citi views the upcoming phase three trial results for AstraZeneca's heart drug Wainua as favorable, expecting positive outcomes that could significantly boost sales. Wainua targets ATTR-cardiomyopathy by suppressing transthyretin protein production, ...
CelLBxHealth PLC has signed a master services agreement with AstraZeneca, enabling it to provide circulating tumour cell (CTC) analytics for AstraZeneca's drug discovery and development. Using its Parsortix platform, CelLBxHealth will analyze CTCs fr...
